Emerging Company Profile
Crossovers Fidelity, Surveyor invest early in ValenzaBio, backing $70M series A for rare autoimmune play
Emerging Company Profile: ValenzaBio readies to take mAbs from CRUK, Pierre Fabre into clinic
After landing mAbs from CRUK and Pierre Fabre, ValenzaBio prepares to challenge established players in autoimmune and inflammatory conditions.
With a $70 million series A round led by Fidelity in a syndicate that included crossover Surveyor, start-up ValenzaBio is readying to take antibodies licensed from CRUK and Pierre Fabre into early clinical testing for rare autoimmune